Association between serum testosterone and measures of cardiovascular health among transgender individuals using gender-affirming testosterone therapy: a cross-sectional study
- PMID: 40528230
- PMCID: PMC12172241
- DOI: 10.1186/s13293-025-00726-3
Association between serum testosterone and measures of cardiovascular health among transgender individuals using gender-affirming testosterone therapy: a cross-sectional study
Abstract
Background: Gender-affirming testosterone therapy (GATT) use may be associated with increased systolic blood pressure (SBP). The association between serum testosterone and cardiovascular health in individuals using GATT is unknown. The objective of this study was to estimate the association between serum testosterone and validated measures of cardiovascular health, including SBP and arterial stiffness, in persons assigned female sex at birth using GATT.
Methods: Healthy participants assigned female sex at birth on a stable GATT regimen for ≥ 4 months were recruited to this community-partnered exploratory cross-sectional study. Exposures of interest were total and free serum testosterone concentration. As our primary outcome, SBP was measured by an automated sphygmomanometer, and carotid-radial pulse wave velocity (PWVcr) and aortic augmentation index (AIx) were used to measure arterial stiffness via applanation tonometry.
Results: Participants (n = 18, median age 28 years, range: 18, 50) who predominantly self-identified as white (94%) and had been using GATT for a median of 48 months (range: 5, 84) were studied. Resting SBP, PWVcr, and AIx were 113 mmHg (range: 102, 129), 7 m/s (range: 4, 9), and 9% (range: - 10, 23), respectively. Total and free serum testosterone were not significantly associated with SBP or PWVcr. Free, but not total, serum testosterone was positively associated with AIx (p = 0.03). Sensitivity analyses did not modify any results.
Conclusions: In healthy transgender individuals, serum testosterone concentrations may not be associated with measures of cardiovascular health. However, these results need to be interpreted with caution given the limited sample size.
Keywords: Arterial stiffness; Blood pressure; Cardiovascular health; Gender-affirming hormone therapy; Serum testosterone; Testosterone; Transgender.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study protocol was approved by the Conjoint Health Research Ethics Board of the University of Calgary (REB19-0460). Written informed consent was obtained from all study participants in accordance with the Declaration of Helsinki. Consent for publication: All authors have given their consent for publication of the manuscript in Biology of Sex Differences. Competing interests: The authors declare no competing interests.
Figures



Similar articles
-
Serum Myostatin is Associated With Central-to-Peripheral Arterial Stiffness Gradient in Healthy Adolescents: The MACISTE Study.Am J Hypertens. 2024 Sep 16;37(10):777-783. doi: 10.1093/ajh/hpae089. Am J Hypertens. 2024. PMID: 39016523
-
The Effect of Gender-Affirming Hormone Therapy on the Risk of Subclinical Atherosclerosis in the Transgender Population: A Systematic Review.Endocr Pract. 2023 Jun;29(6):498-507. doi: 10.1016/j.eprac.2022.12.017. Epub 2023 Jan 2. Endocr Pract. 2023. PMID: 36603652
-
Gender differences in aortic blood pressure, arterial stiffness, and cerebral blood flow in healthy adults: A STROBE-compliant cross-sectional observational study.Medicine (Baltimore). 2025 Jun 6;104(23):e42717. doi: 10.1097/MD.0000000000042717. Medicine (Baltimore). 2025. PMID: 40489811 Free PMC article.
-
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1. MMWR Surveill Summ. 2025. PMID: 40493548 Free PMC article.
-
Systematic Review on Gender-Affirming Testosterone Therapy and the Risk of Breast Cancer: A Challenge for Physicians Treating Patients from Transgender and Gender-Diverse Populations.Arch Sex Behav. 2024 May;53(5):1969-1980. doi: 10.1007/s10508-023-02773-6. Epub 2023 Dec 26. Arch Sex Behav. 2024. PMID: 38148450
References
-
- Alzahrani T, Nguyen T, Ryan A, Dwairy A, McCaffrey J, Yunus R, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. 2019;12(4): e005597. - PubMed
-
- van Zijverden LM, Wiepjes CM, van Diemen JJK, Thijs A, den Heijer M. Cardiovascular disease in transgender people: a systematic review and meta-analysis. Euro J Endocrinol. 2024;190(2):S13–24. - PubMed
-
- Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, Davidge-Pitts CJ, Nippoldt TB, Prokop LJ, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3914–23. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials